Navigation Links
OXYMATIC® 411AF Electronic Oxygen Conserver

ProductsOXYMATIC® 411AF Electronic Oxygen Conserver
Company CHAD Therapeutics, Inc.
Item OXYMATIC® 411AF Electronic Oxygen Conserver
Features 
  • Every Breath Delivery with Built-in Aluminum Body Regulator with Brass Components (Adjustable Continuous Flow)
  • Weighs approximately 1.2 lbs (544 grams) with the battery
  • Provides every-breath or alternate-breath delivery with a built-in regulator.
  • Offers 1-6 lpm flow equivalency settings to service a broad range of patients.
  • Delivers fixed pulse of oxygen within the first 200 milliseconds of inspiration.
  • Easy access to the battery compartment.
    • Description An All-In-One Conserver.

    Offers an average 5:1 increase in usage time at all settings.

    Allows the use of a standard cannula.

    The combination of the OXYMATIC conserver and lightweight cylinders offers ambulatory oxygen patients a superior alternative to liquid oxygen.

    Reliability backed by a 2-year warranty.

    NOTE: Each model has passed the ASTM PS 127-00 regulator ignition safety test.
    Info CHAD Therapeutics, Inc.
    Customer Service: (800) 423-8870
    Web site: http://www.chadtherapeutics.com

    Related medicine products :

    1. OXYMATIC® 401 Electronic Oxygen Conserver
    2. OXYMATIC® 401A Electronic Oxygen Conserver
    3. OXYMATIC® 411A Electronic Oxygen Conserver
    4. OXYMATIC® 411 Electronic Oxygen Conserver
    5. SEQUOIA OXYMATIC® 302 Electronic Oxygen Conserver
    6. SEQUOIA OXYMATIC® 312 Electronic Oxygen Conserver
    7. OXYMATIC® 2400 Electronic Oxygen Conserver
    8. SEQUOIA OXYMATIC® 311 Electronic Oxygen Conserver
    9. MaximEyes Practice Management and Electronic Medical Records Software Solutions
    10. PRAXIS® Electronic Medical Records v. 2.19
    11. MaximEyes Optometric & Ophthalmology Software for Practice Management and Electronic Medical Records
    Breaking Medicine Technology:Patent Expiries of Blockbuster Antibiotics Will Fuel a Decline of More Than 15 Percent in the Community-Acquired Pneumonia Drug Market 2Pivotal Trial Data Demonstrate NeuroPace RNS(R) System Reduced Seizures in People With Epilepsy 2Pivotal Trial Data Demonstrate NeuroPace RNS(R) System Reduced Seizures in People With Epilepsy 3Pivotal Trial Data Demonstrate NeuroPace RNS(R) System Reduced Seizures in People With Epilepsy 4Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 2Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 3Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 4Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 5Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 6QLT Announces Second Quarter Results for 2009 52895 1QLT Announces Second Quarter Results for 2009 52895 2QLT Announces Second Quarter Results for 2009 52895 3QLT Announces Second Quarter Results for 2009 52895 4QLT Announces Second Quarter Results for 2009 52895 5QLT Announces Second Quarter Results for 2009 52895 6QLT Announces Second Quarter Results for 2009 52895 7QLT Announces Second Quarter Results for 2009 52895 8QLT Announces Second Quarter Results for 2009 52895 9QLT Announces Second Quarter Results for 2009 52895 10QLT Announces Second Quarter Results for 2009 52895 11QLT Announces Second Quarter Results for 2009 52895 12QLT Announces Second Quarter Results for 2009 52895 13QLT Announces Second Quarter Results for 2009 52895 14QLT Announces Second Quarter Results for 2009 52895 15QLT Announces Second Quarter Results for 2009 52895 16QLT Announces Second Quarter Results for 2009 52895 17NeoGenomics Reports Second Quarter 2009 Results 13224 1NeoGenomics Reports Second Quarter 2009 Results 13224 2NeoGenomics Reports Second Quarter 2009 Results 13224 3NeoGenomics Reports Second Quarter 2009 Results 13224 4NeoGenomics Reports Second Quarter 2009 Results 13224 5NeoGenomics Reports Second Quarter 2009 Results 13224 6NeoGenomics Reports Second Quarter 2009 Results 13224 7NeoGenomics Reports Second Quarter 2009 Results 13224 8NeoGenomics Reports Second Quarter 2009 Results 13224 9GeneGo Awarded NIH Grant to Develop Pharmacogenomics Software Suite 52890 1GeneGo Awarded NIH Grant to Develop Pharmacogenomics Software Suite 52890 2